Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2008)...te the well-known dangers of first- and secondhand... in the U.S. are smokers. Exposure of a developin...s who smoke affects an estimated 420,000 newborns ...en. , Now, in the first study of its kind, a tea... of newborns, umbilical cord blood to better under...
(Date:12/3/2008)...and PHILADELPHIA, Dec. 3 ...ay that it is waiving a condition relating to a,p...offer to purchase all of,the outstanding shares o...sdaq: GNLB ), for $1.30 per share in cash withou...s. , It is a condition to the completion of...
(Date:12/3/2008)...URG, Sweden, December 3 Cellectric... drug discovery, today announced the,signing of a...ership (TAP) in,the UK, manufacturers of advanced...ement and high throughput screening applications. ...acture the Dynaflow(R)HT System, Cellectricon,s,n...
(Date:12/3/2008)...r. David Dennis will Outline How Technology Can So...Century, , , KINGSTON, ON, Dec. 3 /PRNewsw...Plants Inc. (PPI), is one of four leading experts ...mate Change Conference underway in Poznan , Poland...obal problems in the 20th Century and the role it ...
Breaking Biology Technology:Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 2Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 3Leading Canadian Scientist to speak at UN Climate Change Conference 2
..., , , Eppendorf AG , , , ..., , , , With Eppendorf Biopur p... standard of purity for consumables. Pipette tips,...s and Combitips bearing the Eppendorf , B...of all steps in the production , process. C...
...Gel Cleanup Kit , , Blunt-end Clon...p Gel , Cleanup Kit , , , ,...endorf 5 Prime, Inc. , October 1, 2002, ..., Agarose gel electrophoresis is a method us...s. This method can be taken a step further; the fr...
..., , , Jrgen Frhlich, Helmut Knig and Di...g; Institute for Microbiology , and Wine Re...inz, Germany , Dietmar Kahle, Eppendorf AG...oblem , , , , , , The isol...) from complex , mixed cultures and their c...
CELLocate protocol blocks for 55 m microgrid
Other Biology Technology:A Unique Dimension in Biological Purity 2A Unique Dimension in Biological Purity 3A Unique Dimension in Biological Purity 4Eppendorf Perfectprep Gel Cleanup Kit 2Eppendorf Perfectprep Gel Cleanup Kit 3Eppendorf Perfectprep Gel Cleanup Kit 4Eppendorf Perfectprep Gel Cleanup Kit 5Eppendorf Perfectprep Gel Cleanup Kit 6Isolation of Microorganisms 2Isolation of Microorganisms 3
(Date:12/3/2008)...act in drug trials that individuals can respond ju...ive drug. On the other hand, it is difficult to e...cebos. A team of researchers from Uppsala Univers...variants that can impact the placebo effect and a ...o respond to placebos. , The study, published in...
(Date:12/3/2008)...ding success of the first tandem mission between E... satellites together again to help improve our und... spacecraft, and Envisat, the largest environmenta...ure Radar (SAR) instruments that provide high reso...ning two or more SAR images of the same site, slig...
(Date:12/3/2008)...take place December 14-17, 2008 at the University,...he auspices of BGU,s Jacob Blaustein Institutes fo...f the conference are the United Nations Educationa...Israel,s Ministry for Foreign Affairs, Jewish Nati...im, the global leader in smart water solutions for...
(Date:12/3/2008)... that are high in protein and cereal grains produc... calcium excretion and weaken bones, according to ...ine Society,s Journal of Clinical Endocrinology &...sing the alkali content of the diet, with a pill o... the opposite effect and strengthens skeletal heal...
Breaking Biology News(10 mins):Genes determine whether sugar pills work 2ESA satellites flying in formation 2Ben-Gurion University of the Negev to host 2Calcium and vitamin D may not be the only protection against bone loss 2Aldrichimica Acta Ranked First in Organic Chemistry by Impact Factor 6548 1Aldrichimica Acta Ranked First in Organic Chemistry by Impact Factor 6548 2Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2636 1Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2636 2Brain Cancer Vaccines Immune Response Key to Outcomes 24019 1Brain Cancer Vaccines Immune Response Key to Outcomes 24019 2Kimberly Finder M D Asks 3A Are We Really In an Economic Recession 3F 24014 1Kimberly Finder M D Asks 3A Are We Really In an Economic Recession 3F 24014 2
...t call them the Dirt Doctors, or Sultans of Soil, ...os National Laboratory has a paper in this week,s ...irt. Bacteria, that is, in the highly complex worl...Reveal Great Bacterial Diversity and High Metal To...d John Dunbar, of Los Alamos, Bioscience Division,...
...days is all it takes for a common, non-disease-cau...squamous cell cancer cells in laboratory cultures,...rchers. , "Our results suggest that adeno-associa...y of the population but has no known ill effects, ...fect on healthy cells," said Craig Meyers, Ph.D., ...
...arch teams at Nihon Nohyaku Co., Ltd., Bayer CropS...f broad-spectrum insecticides that show promise as...cts that damage food crops. The insecticides, whic... to activate a novel insecticide target called the...ing problem of insecticide resistance, the researc...
...tor : The open access Public Library of Science - ... where you can see cells moving, be sure to check ..., added by me. , Biologists have a new tool to t...g tissue. , Called two-photon laser-scanning micr... difference between the random wanderings of immat...
Other Biology News:Using computers and DNA to count bacteria 2Study: Harmless virus kills some cancers 2Study: Harmless virus kills some cancers 3Novel compounds show promise as safer, more potent insecticides 2New tool reveals secrets of migrating cells 2New tool reveals secrets of migrating cells 3New tool reveals secrets of migrating cells 4New tool reveals secrets of migrating cells 5
Luminometers
Prolong Gold Antifade Reagent from Invitrogen
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions.
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research
Biology Products: